CLCS (Cell Source) Equity-to-Asset: -64.59 (As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.95
View Full Analysis

What is Cell Source Equity-to-Asset?

Cell Source CLCS +10.38% 35 Equity-to-Asset is -64.59 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cell Source's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-18.54 Mil. Cell Source's Total Assets for the quarter that ended in Dec. 2024 was $0.29 Mil.

The historical rank and industry rank for Cell Source's Equity-to-Asset or its related term are showing as below:

CLCS's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

Cell Source  (OTCPK:CLCS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cell Source Equity-to-Asset Related Terms

Cell Source Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Cell Source's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Equity-to-Asset Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.58 -31.29 -30.82 -80.06 -64.59

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.06 -201.86 -40.28 -71.48 -64.59

CLCS vs EDSA, CTXR, ASBP: Equity-to-Asset Comparison

For the Biotechnology subindustry, Cell Source's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cell Source's Equity-to-Asset falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Equity-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cell Source's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-18.538/0.287
=

Cell Source's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-18.538/0.287
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -64.59 mean?
Cell Source (CLCS) has a Equity-to-Asset of -64.59 as of Dec. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cell Source and its competitors.
Is Cell Source's Equity-to-Asset too high?
Cell Source's current Equity-to-Asset is -64.59. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Equity-to-Asset compare to EDSA and CTXR?
Cell Source's Equity-to-Asset of -64.59 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current Equity-to-Asset is -64.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Equity-to-Asset of -64.59. The current Equity-to-Asset is -64.59. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cell Source (CLCS), the current Equity-to-Asset is -64.59 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price